Adjunctive MMAE reduces the risk of recurrence, hematoma progression, or the need for surgical rescue compared to standard care, without increasing all-cause mortality or stroke, while achieving comparable functional outcomes (mRS 0-2) at 90 days.
No takes yet. Share an insight, caveat, or question.
Shakir et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: